Simultaneously, HDACi can increase CD8+ T cell infiltration and function (such as IFN-γ secretion) in the tumor microenvironment and synergize with immune checkpoint inhibitors (such as anti-PD-1 antibodies) to enhance antitumor effects (Figure 2) [44,71]. Here, CD8A is linked to neoplasm.